RVTY – revvity, inc. (US:NASDAQ)
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
Revvity to Present at Upcoming Investor Conferences
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Barclays PLC from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Revvity, Inc. (NYSE: RVTY) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $145.00 price target on the stock, up previously from $140.00.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com